copper peptide ghk-cu clinical trial skin anti-aging randomized GHK-Cu Peptide Therapy Brea, CA

Funding The authors declare that no funds or grants were received during the preparation of this manuscript

We dont have FDA approval

Karlstad , Hovi P, Husby A, Hrknen T, Selmer RM, Pihlstrm N, Hansen JV, et al

It has demonstrated a strong safety profile and is currently used for non-therapeutic experimental applications only

1968 Apr 27

10 mg vial Concentration: 10 mg 3 mL = 3.333 mg/mL (equivalently 3,333 mcg/mL) Dose in mg: 600 mcg = 0.6 mg Draw volume: 0.6 mg 3.333 mg/mL = 0.18 mL Syringe units: 0.18 mL 100 = 18 units on a U-100 syringe So on the 10 mg vial, one documented dose is a draw to the 18-unit mark